We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

38 hedge funds and large institutions have $512M invested in Neumora Therapeutics in 2023 Q3 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

23.84% more ownership

Funds ownership: 0% → 23.84% (+24%)

Holders
38
Holders Change
+38
Holders Change %
–
% of All Funds
0.6%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
38
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SoftBank Group
SoftBank Group
Japan
+$95.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$70.3M
3
MCMU
MIC Capital Management (UK)
United Kingdom
+$55.7M
4
WT
Wellcome Trust
United Kingdom
+$41.4M
5
AG
Artal Group
Luxembourg
+$35M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SoftBank Group
1
SoftBank Group
Japan
$108M +$95.6M +7,646,916 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$79.4M +$70.3M +5,624,353 New
MCMU
3
MIC Capital Management (UK)
United Kingdom
$62.9M +$55.7M +4,460,700 New
WT
4
Wellcome Trust
United Kingdom
$46.7M +$41.4M +3,309,124 New
AG
5
Artal Group
Luxembourg
$39.5M +$35M +2,802,702 New
Citadel Advisors
6
Citadel Advisors
Florida
$29.7M +$27.1M +2,168,518 New
EC
7
EcoR1 Capital
California
$29.2M +$25.9M +2,071,450 New
APM
8
Avidity Partners Management
Texas
$25.4M +$22.5M +1,800,000 New
HA
9
HHLR Advisors
Cayman Islands
$24M +$21.2M +1,699,313 New
O
10
OrbiMed
New York
$21.2M +$18.7M +1,500,000 New
JJ
11
Johnson & Johnson
New Jersey
$12.9M +$11.4M +912,128 New
SCM
12
Soros Capital Management
New York
$8.3M +$7.35M +588,235 New
Millennium Management
13
Millennium Management
New York
$3.88M +$3.43M +274,748 New
Marshall Wace
14
Marshall Wace
United Kingdom
$3.62M +$3.2M +256,412 New
AI
15
Alphabet Inc
California
$2.82M +$2.49M +199,608 New
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$2.12M +$1.87M +150,000 New
SM
17
Scoggin Management
New York
$2.12M +$1.87M +150,000 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.72M +$1.53M +122,186 New
CAM
19
Cormorant Asset Management
Massachusetts
$1.3M +$1.15M +92,293 New
Goldman Sachs
20
Goldman Sachs
New York
$1.04M +$920K +73,600 New
Two Sigma Investments
21
Two Sigma Investments
New York
$825K +$731K +58,500 New
Norges Bank
22
Norges Bank
Norway
$706K +$625K +50,000 New
Vanguard Group
23
Vanguard Group
Pennsylvania
$706K +$625K +50,000 New
GCM
24
Greenland Capital Management
New York
$672K +$595K +47,613 New
PMEF
25
Point72 Middle East FZE
United Arab Emirates
$617K +$546K +43,713 New
1
2

NMRA Hedge Fund Activity: Q3 2023 in Review

38 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q3 2023, worth a combined $512M.

Buyers outnumbered sellers: 38 funds opened new NMRA positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was SoftBank Group, opening a new position worth an estimated $95.6M.

  • 38 institutional investors held Neumora Therapeutics (NMRA) as of Q3 2023, up from 0 in Q2 2023.
  • Funds reported $512M of Neumora Therapeutics stock for Q3 2023.
  • 38 funds opened new Neumora Therapeutics positions in Q3 2023 and 0 closed out, a net change of +38 holders.
  • The largest Neumora Therapeutics buyer in Q3 2023 was SoftBank Group, an estimated $95.6M added.

Based on aggregated 13F filings for Q3 2023.